PFE Jul 2024 27.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:40PM EDT. Market open.
| Previous Close | 1.2500 |
| Open | 1.1200 |
| Bid | 1.2500 |
| Ask | 1.2800 |
| Strike | 27.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.9800 - 1.2900 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 9.25k |
Investor's Business DailySarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
Barrons.comPfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
The drug company said a gene therapy it is testing failed to improve motor function in boys aged 4 to 7.
ZacksPfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
© 2024 Yahoo. All rights reserved.